InnoCan Pharma Corporation
INNO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.82M | 7.01M | 7.80M | 5.40M | 8.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.82M | 7.01M | 7.80M | 5.40M | 8.62M |
| Cost of Revenue | 631.00K | 811.00K | 681.00K | 992.00K | 845.00K |
| Gross Profit | 6.19M | 6.20M | 7.12M | 4.41M | 7.78M |
| SG&A Expenses | 6.99M | 5.62M | 6.45M | 5.01M | 7.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.04M | 6.61M | 7.31M | 6.32M | 8.27M |
| Operating Income | -1.22M | 396.00K | 489.00K | -919.00K | 352.00K |
| Income Before Tax | -1.43M | -109.00K | 33.00K | 3.00K | 702.00K |
| Income Tax Expenses | 220.00K | 206.00K | 262.00K | 51.00K | 418.00K |
| Earnings from Continuing Operations | -1.65M | -315.00K | -229.00K | -48.00K | 284.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -295.00K | -275.00K | -353.00K | -66.00K | -574.00K |
| Net Income | -1.95M | -590.00K | -582.00K | -114.00K | -290.00K |
| EBIT | -1.22M | 396.00K | 489.00K | -919.00K | 352.00K |
| EBITDA | -1.21M | 405.00K | 499.00K | -913.00K | 361.00K |
| EPS Basic | -0.43 | -0.13 | -0.13 | -0.03 | -0.07 |
| Normalized Basic EPS | -0.25 | -0.06 | -0.07 | -0.01 | -0.03 |
| EPS Diluted | -0.43 | -0.13 | -0.13 | -0.03 | -0.07 |
| Normalized Diluted EPS | -0.25 | -0.06 | -0.07 | -0.01 | -0.03 |
| Average Basic Shares Outstanding | 4.50M | 4.50M | 4.47M | 4.42M | 4.33M |
| Average Diluted Shares Outstanding | 4.50M | 4.50M | 4.47M | 4.42M | 4.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |